Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 36

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections

Atshan, Salman Sahab, Hamat, Rukman Awang, Aljaberi, Musheer A., Chen, Jung-Sheng, Huang, Shih-Wei, Lin, Chung-Ying, Mullins, Benjamin J., Kicic, Anthony·2023·Antibiotics

Abstract

The production and use of antibiotics increased significantly after the Second World War due to their effectiveness against bacterial infections. However, bacterial resistance also emerged and has now become an important global issue. Those most in need are typically high-risk and include individuals who experience burns and other wounds, as well as those with pulmonary infections caused by antibiotic-resistant bacteria, such as Pseudomonas aeruginosa, Acinetobacter sp, and Staphylococci. With investment to develop new antibiotics waning, finding and developing alternative therapeutic strategies to tackle this issue is imperative. One option remerging in popularity is bacteriophage (phage) therapy. This review focuses on Staphylococcus aureus and how it has developed resistance to antibiotics. It also discusses the potential of phage therapy in this setting and its appropriateness in high-risk people, such as those with cystic fibrosis, where it typically forms a biofilm.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/antibiotics12020286

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 164

  1. Su, 2019, Genome-based prediction of bacterial antibiotic resistance, J. Clin. Microbiol., 57, e01405, 10.1128/JCM.01405-18 · DOI · Paper page
  2. Trend, 2017, The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways, J. Cyst. Fibros., 16, 663, 10.1016/j.jcf.2017.06.012 · DOI
  3. Kodong, 2020, The monitoring infectious diseases diffusion through GIS, SciTech Framew., 2, 23
  4. Pincus, N.B., Reckhow, J.D., Saleem, D., Jammeh, M.L., Datta, S.K., and Myles, I.A. (2015). Strain Specific Phage Treatment for Staphylococcus aureus Infection Is Influenced by Host Immunity and Site of Infection. PLoS ONE, 10. · DOI
  5. Breederveld, 2019, Phage therapy 2.0: Where do we stand?, Lancet Infect. Dis., 19, 2, 10.1016/S1473-3099(18)30502-4 · doi:10.1016/s1473-3099(18)30502-4
  6. Fish, R., Kutter, E., Bryan, D., Wheat, G., and Kuhl, S. (2018). Resolving Digital Staphylococcal Osteomyelitis Using Bacteriophage—A Case Report. Antibiotics, 7. · doi:10.3390/antibiotics7040087
  7. Morozova, 2018, Applications of Bacteriophages in the Treatment of Localized Infections in Humans, Front. Microbiol., 9, 1696, 10.3389/fmicb.2018.01696 · DOI
  8. Lin, 2020, Safety of bacteriophage therapy in severe Staphylococcus aureus infection, Nat. Microbiol., 5, 465, 10.1038/s41564-019-0634-z · DOI · Paper page
  9. Oduor, J.M.O., Kadija, E., Nyachieo, A., Mureithi, M.W., and Skurnik, M. (2020). Bioprospecting Staphylococcus Phages with Therapeutic and Bio-Control Potential. Viruses, 12. · DOI
  10. Kornienko, 2020, Contribution of Podoviridae and Myoviridae bacteriophages to the effectiveness of anti-staphylococcal therapeutic cocktails, Sci. Rep., 10, 18612, 10.1038/s41598-020-75637-x · doi:10.1038/s41598-020-75637-x
  11. McCallin, 2018, Metagenome analysis of Russian and Georgian Pyophage cocktails and a placebo-controlled safety trial of single phage versus phage cocktail in healthy Staphylococcus aureus carriers, Environ. Microbiol., 20, 3278, 10.1111/1462-2920.14310 · DOI
  12. Romero-Calle, D., Guimarães Benevides, R., Góes-Neto, A., and Billington, C. (2019). Bacteriophages as Alternatives to Antibiotics in Clinical Care. Antibiotics, 8. · DOI · Paper page
  13. Kållberg, C., Årdal, C., Salvesen Blix, H., Klein, E., Martinez, E.M., Lindbæk, M., Outterson, K., Røttingen, J.-A., and Laxminarayan, R. (2018). Introduction and geographic availability of new antibiotics approved between 1999 and 2014. PLoS ONE, 13. · DOI
  14. Esteban, 2013, In vitro susceptibility to antibiotics of staphylococci in biofilms isolated from orthopaedic infections, Int. J. Antimicrob. Agents, 41, 521, 10.1016/j.ijantimicag.2013.02.018 · DOI
  15. Kreiswirth, 1993, Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus, Science, 259, 227, 10.1126/science.8093647 · DOI · Paper page
  16. Rad, E.G. (2010). Molecular Epidemiology and Therapeutic Potential of Persian Shallot (Allium ascalonicum L.) in the Management of Methicillin Resistant Staphylococcus Aureus Infection. [Ph.D. Thesis, Universiti Putra Malaysia].
  17. Dickmann, 2017, Communicating the Risk of MRSA: The Role of Clinical Practice, Regulation and Other Policies in Five European Countries, Front. Public Health, 5, 44, 10.3389/fpubh.2017.00044 · DOI
  18. Ji, Y. (2007). Methicillin-Resistant Staphylococcus aureus (MRSA) Protocols, Humana Press. · doi:10.1007/978-1-59745-468-1
  19. Partridge, 2018, Mobile genetic elements associated with antimicrobial resistance, Clin. Microbiol. Rev., 31, e00088-17, 10.1128/CMR.00088-17 · DOI · Paper page
  20. Seemann, 2010, Complete Genome Sequence of Staphylococcus aureus Strain JKD6008, an ST239 Clone of Methicillin-Resistant Staphylococcus aureus with Intermediate-Level Vancomycin Resistance, J. Bacteriol., 192, 5848, 10.1128/JB.00951-10 · doi:10.1128/jb.00951-10
  21. Pang, 2020, The Genomic Context for the Evolution and Transmission of Community-Associated Staphylococcus aureus ST59 Through the Food Chain, Front. Microbiol., 11, 422, 10.3389/fmicb.2020.00422 · DOI
  22. Hallin, 2009, StaphVar-DNA microarray analysis of accessory genome elements of community-acquired methicillin-resistant Staphylococcus aureus, J. Antimicrob. Chemother., 63, 877, 10.1093/jac/dkp089 · DOI
  23. Toft, 2020, Core genome multi-locus sequence typing as an essential tool in a high-cost livestock-associated meticillin-resistant Staphylococcus aureus CC398 hospital outbreak, J. Hosp. Infect., 104, 574, 10.1016/j.jhin.2019.12.009 · doi:10.1016/j.jhin.2019.12.009
  24. Balaky, S. (2011). The Effect of Antibiotics on Toxin Gene Expression in PVL-positive Staphylococcus aureus Strains. [Ph.D. Thesis, Durham University].
  25. Holden, 2004, Complete genomes of two clinical Staphylococcus aureus strains: Evidence for the rapid evolution of virulence and drug resistance, Proc. Natl. Acad. Sci. USA, 101, 9786, 10.1073/pnas.0402521101 · DOI · Paper page
  26. Ioanas, 2004, Linezolid in VAP by MRSA: A better choice?, Intensive Care Med., 30, 343, 10.1007/s00134-003-2135-y · DOI
  27. Livermore, 2003, Linezolid in vitro: Mechanism and antibacterial spectrum, J. Antimicrob. Chemother., 51, ii9, 10.1093/jac/dkg249 · DOI · Paper page
  28. Ito, 2004, Novel Type V Staphylococcal Cassette Chromosome mec Driven by a Novel Cassette Chromosome Recombinase, ccrC, Antimicrob. Agents Chemother., 48, 2637, 10.1128/AAC.48.7.2637-2651.2004 · DOI · Paper page
  29. Zhang, 2009, Novel Staphylococcal Cassette Chromosome mec Type, Tentatively Designated Type VIII, Harboring Class A mec and Type 4 ccr Gene Complexes in a Canadian Epidemic Strain of Methicillin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 531, 10.1128/AAC.01118-08 · DOI · Paper page
  30. Lakhundi, 2018, Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology, Clin. Microbiol. Rev., 31, e00020-18, 10.1128/CMR.00020-18 · DOI · Paper page
  31. Chongtrakool, 2006, Staphylococcal Cassette Chromosome mec (SCCmec) Typing of Methicillin-Resistant Staphylococcus aureus Strains Isolated in 11 Asian Countries: A Proposal for a New Nomenclature for SCCmec Elements, Antimicrob. Agents Chemother., 50, 1001, 10.1128/AAC.50.3.1001-1012.2006 · DOI · Paper page
  32. Rasmussen, 2010, Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA, Future Microbiol., 6, 43, 10.2217/fmb.10.155 · DOI
  33. Kavanagh, 2018, View point: Gaps in the current guidelines for the prevention of Methicillin-resistant Staphylococcus aureus surgical site infections, Antimicrob. Resist. Infect. Control, 7, 112, 10.1186/s13756-018-0407-0 · doi:10.1186/s13756-018-0407-0
  34. Brown, 2021, Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK, JAC-Antimicrob. Resist., 3, dlaa114, 10.1093/jacamr/dlaa114 · DOI · Paper page
  35. Vonberg, 2011, Worldwide Outbreak Database: The largest collection of nosocomial outbreaks, Infection, 39, 29, 10.1007/s15010-010-0064-6 · doi:10.1007/s15010-010-0064-6
  36. Rubin, 2018, A Sporadic Four-Year Hospital Outbreak of a ST97-IVa MRSA With Half of the Patients First Identified in the Community, Front. Microbiol., 9, 1494, 10.3389/fmicb.2018.01494 · doi:10.3389/fmicb.2018.01494
  37. Talan, 2016, Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess, N. Engl. J. Med., 374, 823, 10.1056/NEJMoa1507476 · DOI · Paper page
  38. Talan, 2018, Subgroup Analysis of Antibiotic Treatment for Skin Abscesses, Ann. Emerg. Med., 71, 21, 10.1016/j.annemergmed.2017.07.483 · DOI
  39. Nathwani, 2008, Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community, J. Antimicrob. Chemother., 61, 976, 10.1093/jac/dkn096 · DOI · Paper page
  40. Tanus, 2014, A Randomized, Double-blind, Comparative Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment 1% Versus Oral Linezolid in the Treatment of Secondarily Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus, Adv. Ski. Wound Care, 27, 548, 10.1097/01.ASW.0000456631.20389.ae · DOI
  41. Noel, 2008, A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections, Clin. Infect. Dis., 46, 647, 10.1086/526527 · DOI · Paper page
  42. Boucher, 2014, Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection, New Engl. J. Med., 370, 2169, 10.1056/NEJMoa1310480 · DOI · Paper page
  43. Moran, 2014, Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial, Lancet Infect. Dis., 14, 696, 10.1016/S1473-3099(14)70737-6 · DOI · Paper page
  44. John, 2020, The treatment of resistant staphylococcal infections, F1000Research, 9, 150, 10.12688/f1000research.17718.1 · doi:10.12688/f1000research.17718.1
  45. Gould, 2009, Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom, J. Antimicrob. Chemother., 63, 849, 10.1093/jac/dkp065 · DOI
  46. Rubinstein, 2011, Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens, Clin. Infect. Dis., 52, 31, 10.1093/cid/ciq031 · DOI · Paper page
  47. Thitiananpakorn, 2020, Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA), Sci. Rep., 10, 16107, 10.1038/s41598-020-73108-x · DOI
  48. Puttagunta, 2015, Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue, Antimicrob. Agents Chemother., 59, 1849, 10.1128/AAC.04550-14 · DOI · Paper page
  49. Filippone, 2017, The Nephrotoxicity of Vancomycin, Clin. Pharmacol. Ther., 102, 459, 10.1002/cpt.726 · DOI · Paper page
  50. Liu, 2011, Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children, Clin. Infect. Dis., 52, e18, 10.1093/cid/ciq146 · DOI · Paper page
  51. Choo, 2016, Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia, Infect. Chemother., 48, 267, 10.3947/ic.2016.48.4.267 · DOI · Paper page
  52. Demir, 2022, How Safe Is the Use of Intrathecal Vancomycin?, World Neurosurg., 160, e55, 10.1016/j.wneu.2021.12.082 · doi:10.1016/j.wneu.2021.12.082
  53. Gould, 2012, Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: A report of the Working Party of the British Society for Antimicrobial Chemotherapy, J. Antimicrob. Chemother., 67, 269, 10.1093/jac/dkr450 · DOI · Paper page
  54. Morrisette, T., Alosaimy, S., Abdul-Mutakabbir, J.C., Kebriaei, R., and Rybak, M.J. (2020). The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy. Antibiotics, 9. · DOI
  55. Aslam, 2018, Antibiotic resistance: A rundown of a global crisis, Infect. Drug Resist., 11, 1645, 10.2147/IDR.S173867 · DOI · Paper page
  56. Cong, 2020, Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features, J. Adv. Res., 21, 169, 10.1016/j.jare.2019.10.005 · DOI · Paper page
  57. Robinson, 2003, Evolutionary Models of the Emergence of Methicillin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 47, 3926, 10.1128/AAC.47.12.3926-3934.2003 · DOI · Paper page
  58. Rolo, J., Worning, P., Boye Nielsen, J., Sobral, R., Bowden, R., Bouchami, O., Damborg, P., Guardabassi, L., Perreten, V., and Westh, H. (2017). Evidence for the evolutionary steps leading to mecA-mediated β-lactam resistance in staphylococci. PLOS Genet., 13. · DOI
  59. Babakhani, 2018, Transposons: The agents of antibiotic resistance in bacteria, J. Basic Microbiol., 58, 905, 10.1002/jobm.201800204 · DOI · Paper page
  60. Pillar, 2008, Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: Findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs, Diagn. Microbiol. Infect. Dis., 60, 221, 10.1016/j.diagmicrobio.2007.08.007 · DOI
  61. National Nosocomial Infections Surveillance System (2003). National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control, 31, 481–498. · DOI · Paper page
  62. National Nosocomial Infections Surveillance System (2004). National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control, 32, 470–485. · DOI · Paper page
  63. Ehsanollah, 2009, Anti-adhesive and anti-invasive activities of an oil based di-herbal extract against methicillin resistant Staphylococcus aureus, Afr. J. Microbiol. Res., 3, 272
  64. Appelbaum, 2004, Vancomycin resistance in Staphylococcus aureus, Clin. Lab. Med., 24, 381, 10.1016/j.cll.2004.03.004 · DOI · Paper page
  65. Tenover, 2005, Vancomycin-resistant staphylococci and enterococci: Epidemiology and control, Curr. Opin. Infect. Dis., 18, 300, 10.1097/01.qco.0000171923.62699.0c · DOI · Paper page
  66. Brown, 2005, Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA), J. Antimicrob. Chemother., 56, 1000, 10.1093/jac/dki372 · DOI · Paper page
  67. Sauvage, 2008, The penicillin-binding proteins: Structure and role in peptidoglycan biosynthesis, FEMS Microbiol. Rev., 32, 234, 10.1111/j.1574-6976.2008.00105.x · DOI · Paper page
  68. Bauer, 1966, Antibiotic susceptibility testing by a standardized single disc method, Am. J. Clin. Pathol., 45, 149, 10.1093/ajcp/45.4_ts.493 · DOI · Paper page
  69. Foster, 2017, Antibiotic resistance in Staphylococcus aureus. Current status and future prospects, FEMS Microbiol. Rev., 41, 430, 10.1093/femsre/fux007 · DOI · Paper page
  70. Jevons, 1961, Celebin-resistant staphylococci, Br Med. J., 1, 124, 10.1136/bmj.1.5219.124-a · DOI · Paper page
  71. 2015, Staphylococcal Cassette Chromosome mec (SCCmec) in coagulase negative staphylococci, Med. Univ., 17, 229
  72. Antignac, 2009, Reconstruction of the Phenotypes of Methicillin-Resistant Staphylococcus aureus by Replacement of the Staphylococcal Cassette Chromosome mec with a Plasmid-Borne Copy of Staphylococcus sciuri pbpD Gene, Antimicrob. Agents Chemother., 53, 435, 10.1128/AAC.01099-08 · DOI
  73. 2003, Methicillin (Oxacillin)-Resistant Staphylococcus aureus Strains Isolated from Major Food Animals and Their Potential Transmission to Humans, Appl. Environ. Microbiol., 69, 6489, 10.1128/AEM.69.11.6489-6494.2003 · DOI · Paper page
  74. Katzif, 2005, CspA Regulates Pigment Production in Staphylococcus aureus through a SigB-Dependent Mechanism, J. Bacteriol., 187, 8181, 10.1128/JB.187.23.8181-8184.2005 · DOI
  75. Courvalin, 2009, VanA-Type Vancomycin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 4580, 10.1128/AAC.00346-09 · DOI · Paper page
  76. Mussa, 2022, Acquired tetracycline resistance genes by transposons and virulence factors in enterococci recovered from overland and aquatic animals: A systematic review, Rev. Aquac., 14, 399, 10.1111/raq.12605 · DOI
  77. Andersson, 2010, Antibiotic resistance and its cost: Is it possible to reverse resistance?, Nat. Rev. Microbiol., 8, 260, 10.1038/nrmicro2319 · DOI · Paper page
  78. Monroe, D. (2007). Looking for Chinks in the Armor of Bacterial Biofilms. PLOS Biol., 5. · DOI · Paper page
  79. Keren, 2004, Persister cells and tolerance to antimicrobials, FEMS Microbiol. Lett., 230, 13, 10.1016/S0378-1097(03)00856-5 · DOI · Paper page
  80. Hsu, 2005, Dissemination of Multisusceptible Methicillin-Resistant Staphylococcus aureus in Singapore, J. Clin. Microbiol., 43, 2923, 10.1128/JCM.43.6.2923-2925.2005 · DOI
  81. Mah, 2001, Mechanisms of biofilm resistance to antimicrobial agents, Trends Microbiol., 9, 34, 10.1016/S0966-842X(00)01913-2 · DOI · Paper page
  82. Stenz, L. (2011). The GTP-Dependant Pleiotropic Repressor” CodY” Regulates Biofilm Formation in Staphylococcus aureus. [Ph.D. Thesis, University of Geneva].
  83. Lebeaux, 2014, Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics, Microbiol. Mol. Biol. Rev., 78, 510, 10.1128/MMBR.00013-14 · DOI · Paper page
  84. Akturk, E., Oliveira, H., Santos, S.B., Costa, S., Kuyumcu, S., Melo, L.D.R., and Azeredo, J. (2019). Synergistic Action of Phage and Antibiotics: Parameters to Enhance the Killing Efficacy Against Mono and Dual-Species Biofilms. Antibiotics, 8. · DOI · Paper page
  85. Dickey, J., and Perrot, V. (2019). Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro. PLoS ONE, 14. · doi:10.1371/journal.pone.0209390
  86. Wang, 2020, Evaluation of Staphylococcal Bacteriophage Sb-1 as an Adjunctive Agent to Antibiotics Against Rifampin-Resistant Staphylococcus aureus Biofilms, Front. Microbiol., 11, 602057, 10.3389/fmicb.2020.602057 · DOI
  87. Pires, 2022, An overview of the current state of phage therapy for the treatment of biofilm-related infections, Curr. Opin. Virol., 53, 101209, 10.1016/j.coviro.2022.101209 · doi:10.1016/j.coviro.2022.101209
  88. Atshan, S.S., Hamat, R.A., Coolen, M.J.L., Dykes, G., Sekawi, Z., Mullins, B.J., Than, L.T., Abduljaleel, S.A., and Kicic, A. (2021). The Role of Subinhibitory Concentrations of Daptomycin and Tigecycline in Modulating Virulence in Staphylococcus aureus. Antibiotics, 10. · doi:10.3390/antibiotics10010039
  89. Chan, 2013, Phage cocktails and the future of phage therapy, Future Microbiol., 8, 769, 10.2217/fmb.13.47 · DOI · Paper page
  90. Reza, 2014, Dynamics of bacteriophages as a promising antibiofilm agents, J. Pure Appl. Microbiol., 8, 1015
  91. Miernikiewicz, P., Dąbrowska, K., Piotrowicz, A., Owczarek, B., Wojas-Turek, J., Kicielińska, J., Rossowska, J., Pajtasz-Piasecka, E., Hodyra, K., and Macegoniuk, K. (2013). T4 Phage and Its Head Surface Proteins Do Not Stimulate Inflammatory Mediator Production. PLoS ONE, 8. · DOI
  92. Letarov, 2017, Adsorption of bacteriophages on bacterial cells, Biochem., 82, 1632
  93. Twort, 1961, An investigation on the nature of ultra-microscopic viruses, Acta Kravsi, 189, 1241
  94. 1917, On an invisible microbe antagonistic to dysentery bacilli, CR Acad. Sci., 165, 373
  95. Abedon, 2011, Phage treatment of human infections, Bacteriophage, 1, 66, 10.4161/bact.1.2.15845 · DOI · Paper page
  96. Szybalski, 2012, Chapter 3—Clinical Aspects of Phage Therapy, Advances in Virus Research, Volume 83, 73, 10.1016/B978-0-12-394438-2.00003-7 · DOI · Paper page
  97. Chanishvili, N. (2012). Literature Review of the Practical Application of Bacteriophage Research, Nova Science Publishers, Incorporated.
  98. Laskin, 2012, Chapter 1—Phage Therapy Pharmacology: Phage Cocktails, Advances in Applied Microbiology, Volume 78, 1, 10.1016/B978-0-12-394805-2.00001-4 · DOI · Paper page
  99. Levin, 2004, Population and evolutionary dynamics of phage therapy, Nat. Rev. Microbiol., 2, 166, 10.1038/nrmicro822 · DOI · Paper page
  100. Carvalho, C.M., Gannon, B.W., Halfhide, D.E., Santos, S.B., Hayes, C.M., Roe, J.M., and Azeredo, J. (2010). The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens. BMC Microbiol., 10. · DOI · Paper page
  101. Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., and Van Parys, L. (2009). Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical Trials. PLoS ONE, 4. · DOI · Paper page
  102. Viazis, 2011, Reduction of Escherichia coli O157:H7 viability on hard surfaces by treatment with a bacteriophage mixture, Int. J. Food Microbiol., 145, 37, 10.1016/j.ijfoodmicro.2010.11.021 · doi:10.1016/j.ijfoodmicro.2010.11.021
  103. Mitchell, 2019, Mini-review: Efficacy of lytic bacteriophages on multispecies biofilms, Biofouling, 35, 472, 10.1080/08927014.2019.1613525 · DOI
  104. Tian, 2021, Bacteriophage—A Promising Alternative Measure for Bacterial Biofilm Control, Infect. Drug Resist., 14, 205, 10.2147/IDR.S290093 · DOI
  105. 2016, Bacteriophages as Weapons Against Bacterial Biofilms in the Food Industry, Front. Microbiol., 7, 825
  106. Sousa, 2014, Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs—A Review, Pathogens, 3, 680, 10.3390/pathogens3030680 · DOI · Paper page
  107. Wright, 2009, A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy, Clin. Otolaryngol., 34, 349, 10.1111/j.1749-4486.2009.01973.x · DOI · Paper page
  108. Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y., Zhao, H., Gao, Y., Song, J., and Lu, R. (2012). A Method for Generation Phage Cocktail with Great Therapeutic Potential. PLoS ONE, 7. · DOI · Paper page
  109. Chaudhry, W.N., Concepción-Acevedo, J., Park, T., Andleeb, S., Bull, J.J., and Levin, B.R. (2017). Synergy and Order Effects of Antibiotics and Phages in Killing Pseudomonas aeruginosa Biofilms. PLoS ONE, 12. · DOI · Paper page
  110. Tagliaferri, 2019, Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy, Front. Cell. Infect. Microbiol., 9, 22, 10.3389/fcimb.2019.00022 · DOI · Paper page
  111. Trend, 2018, Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis, Front. Pharmacol., 9, 1330, 10.3389/fphar.2018.01330 · DOI
  112. Estrella, 2016, Characterization of novel Staphylococcus aureus lytic phage and defining their combinatorial virulence using the OmniLog® system, Bacteriophage, 6, e1219440, 10.1080/21597081.2016.1219440 · DOI
  113. Wunderink, 2012, Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study, Clin. Infect. Dis., 54, 621, 10.1093/cid/cir895 · DOI · Paper page
  114. Lee, 2018, Methicillin-resistant Staphylococcus aureus, Nat. Rev. Dis. Prim., 4, 18033, 10.1038/nrdp.2018.33 · DOI · Paper page
  115. Stewart, 2008, Physiological heterogeneity in biofilms, Nat. Rev. Microbiol., 6, 199, 10.1038/nrmicro1838 · DOI · Paper page
  116. Garner, 2012, The Relative Contributions of Physical Structure and Cell Density to the Antibiotic Susceptibility of Bacteria in Biofilms, Antimicrob. Agents Chemother., 56, 2967, 10.1128/AAC.06480-11 · DOI · Paper page
  117. Lehman, S.M., Mearns, G., Rankin, D., Cole, R.A., Smrekar, F., Branston, S.D., and Morales, S. (2019). Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Staphylococcus aureus Infections. Viruses, 11. · DOI
  118. Chhibber, 2017, Transfersomal Phage Cocktail Is an Effective Treatment against Methicillin-Resistant Staphylococcus aureus-Mediated Skin and Soft Tissue Infections, Antimicrob. Agents Chemother., 61, e02146-16, 10.1128/AAC.02146-16 · DOI
  119. Prazak, 2019, Bacteriophages Improve Outcomes in Experimental Staphylococcus aureus Ventilator-associated Pneumonia, Am. J. Respir. Crit. Care Med., 200, 1126, 10.1164/rccm.201812-2372OC · doi:10.1164/rccm.201812-2372oc
  120. Rahman, 2011, Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin, Biofouling, 27, 1087, 10.1080/08927014.2011.631169 · doi:10.1080/08927014.2011.631169
  121. Lin, 2017, Phage therapy: An alternative to antibiotics in the age of multi-drug resistance, World J. Gastrointest. Pharmacol. Ther., 8, 162, 10.4292/wjgpt.v8.i3.162 · DOI · Paper page
  122. Kumaran, 2018, Does Treatment Order Matter? Investigating the Ability of Bacteriophage to Augment Antibiotic Activity against Staphylococcus aureus Biofilms, Front. Microbiol., 9, 127, 10.3389/fmicb.2018.00127 · DOI
  123. Shimamori, Y., Mitsunaka, S., Yamashita, H., Suzuki, T., Kitao, T., Kubori, T., Nagai, H., Takeda, S., and Ando, H. (2020). Staphylococcal Phage in Combination with Staphylococcus epidermidis as a Potential Treatment for Staphylococcus aureus-Associated Atopic Dermatitis and Suppressor of Phage-Resistant Mutants. Viruses, 13. · DOI
  124. Brives, 2020, Phage therapy as a potential solution in the fight against AMR: Obstacles and possible futures, Palgrave Commun., 6, 100, 10.1057/s41599-020-0478-4 · DOI · Paper page
  125. Kortright, 2019, Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria, Cell Host Microbe, 25, 219, 10.1016/j.chom.2019.01.014 · DOI · Paper page
  126. Aslam, 2019, Novel bacteriophage therapy for treatment of left ventricular assist device infection, J. Heart Lung Transplant., 38, 475, 10.1016/j.healun.2019.01.001 · doi:10.1016/j.healun.2019.01.001
  127. Doub, J.B., Ng, V.Y., Johnson, A.J., Slomka, M., Fackler, J., Horne, B.A., Brownstein, M.J., Henry, M., Malagon, F., and Biswas, B. (2020). Salvage Bacteriophage Therapy for a Chronic MRSA Prosthetic Joint Infection. Antibiotics, 9. · doi:10.3390/antibiotics9050241
  128. Gilbey, 2019, Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus, Med. J. Aust., 211, 142, 10.5694/mja2.50274 · doi:10.5694/mja2.50274
  129. Ferry, 2020, The Potential Innovative Use of Bacteriophages Within the DAC® Hydrogel to Treat Patients With Knee Megaprosthesis Infection Requiring “Debridement Antibiotics and Implant Retention” and Soft Tissue Coverage as Salvage Therapy, Front. Med., 7, 342, 10.3389/fmed.2020.00342 · DOI
  130. Ferry, 2020, Phage Therapy as Adjuvant to Conservative Surgery and Antibiotics to Salvage Patients With Relapsing S. aureus Prosthetic Knee Infection, Front. Med., 7, 570572, 10.3389/fmed.2020.570572 · doi:10.3389/fmed.2020.570572
  131. Rubalskii, E., Ruemke, S., Salmoukas, C., Boyle, E.C., Warnecke, G., Tudorache, I., Shrestha, M., Schmitto, J.D., Martens, A., and Rojas, S.V. (2020). Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery. Antibiotics, 9. · DOI
  132. Ramirez-Sanchez, C., Gonzales, F., Buckley, M., Biswas, B., Henry, M., Deschenes, M.V., Horne, B.A., Fackler, J., Brownstein, M.J., and Schooley, R.T. (2021). Successful Treatment of Staphylococcus aureus Prosthetic Joint Infection with Bacteriophage Therapy. Viruses, 13. · doi:10.3390/v13061182
  133. Rojas, S.V., Junghans, S., Fox, H., Lazouski, K., Schramm, R., Morshuis, M., Gummert, J.F., and Gross, J. (2022). Bacteriophage-Enriched Galenic for Intrapericardial Ventricular Assist Device Infection. Antibiotics, 11. · doi:10.3390/antibiotics11050602
  134. Püschel, A., Skusa, R., Bollensdorf, A., and Gross, J. (2022). Local Treatment of Driveline Infection with Bacteriophages. Antibiotics, 11. · doi:10.3390/antibiotics11101310
  135. Doub, J.B., Ng, V.Y., Lee, M., Chi, A., Lee, A., Würstle, S., and Chan, B. (2022). Salphage: Salvage Bacteriophage Therapy for Recalcitrant MRSA Prosthetic Joint Infection. Antibiotics, 11. · doi:10.3390/antibiotics11050616
  136. Schoeffel, J., Wang, E.W., Gill, D., Frackler, J., Horne, B.A., Manson, T., and Doub, J.B. (2022). Successful Use of Salvage Bacteriophage Therapy for a Recalcitrant MRSA Knee and Hip Prosthetic Joint Infection. Pharmaceuticals, 15. · doi:10.3390/ph15020177
  137. Grambow, 2022, Treatment of an Infected TEVAR with Extra- and Endovascular Bacteriophage Application, EJVES Vasc. Forum, 56, 20, 10.1016/j.ejvsvf.2022.02.004 · doi:10.1016/j.ejvsvf.2022.02.004
  138. Onsea, J., Soentjens, P., Djebara, S., Merabishvili, M., Depypere, M., Spriet, I., De Munter, P., Debaveye, Y., Nijs, S., and Vanderschot, P. (2019). Bacteriophage Application for Difficult-To-Treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. Viruses, 11. · DOI · Paper page
  139. Nadareishvili, 2020, Bacteriophage Therapy as a Potential Management Option for Surgical Wound Infections, PHAGE, 1, 158, 10.1089/phage.2020.0010 · DOI
  140. Van Nieuwenhuyse, B., Galant, C., Brichard, B., Docquier, P.-L., Djebara, S., Pirnay, J.-P., Van der Linden, D., Merabishvili, M., and Chatzis, O. (2021). A Case of In Situ Phage Therapy against Staphylococcus aureus in a Bone Allograft Polymicrobial Biofilm Infection: Outcomes and Phage-Antibiotic Interactions. Viruses, 13. · DOI
  141. Gupta, 2019, Bacteriophage Therapy of Chronic Nonhealing Wound: Clinical Study, Int. J. Low. Extrem. Wounds, 18, 171, 10.1177/1534734619835115 · DOI
  142. Rodriguez, 2022, Case Report: Successful use of phage therapy in refractory MRSA chronic rhinosinusitis, Int. J. Infect. Dis., 121, 14, 10.1016/j.ijid.2022.04.049 · doi:10.1016/j.ijid.2022.04.049
  143. Bleibtreu, 2020, Combining bacteriophages and dalbavancin for salvage therapy of complex Staphylococcus aureus extradural empyema, Médecine Mal. Infect., 50, 458, 10.1016/j.medmal.2020.02.004 · doi:10.1016/j.medmal.2020.02.004
  144. Johri, 2021, Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments, Front. Pharmacol., 12, 692614, 10.3389/fphar.2021.692614 · DOI
  145. Moorthy, 2022, Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection Clin, Infect. Dis., 75, 338, 10.1093/cid/ciab1015 · doi:10.1093/cid/ciab1015
  146. Schuch, 2017, Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent, Antimicrob. Agents Chemother., 61, e02666-16, 10.1128/AAC.02666-16 · DOI · Paper page
  147. Khullar, 2022, Exploring the therapeutic potential of staphylococcal phage formulations: Current challenges and applications in phage therapy, J. Appl. Microbiol., 132, 3515, 10.1111/jam.15462 · DOI
  148. Danis-Wlodarczyk, K.M., Wozniak, D.J., and Abedon, S.T. (2021). Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application. Antibiotics, 10. · DOI
  149. Krylov, 2001, Phagotherapy in terms of bacteriophage genetics: Hopes, perspectives, safety, limitations, Genetika, 37, 869
  150. Huh, 2019, Bacteriophage interactions with mammalian tissue: Therapeutic applications, Adv. Drug Deliv. Rev., 145, 4, 10.1016/j.addr.2019.01.003 · DOI · Paper page
  151. Guerin, 2020, Shining Light on Human Gut Bacteriophages, Front. Cell. Infect. Microbiol., 10, 481, 10.3389/fcimb.2020.00481 · DOI
  152. Barrow, 1997, Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential, Trends Microbiol., 5, 268, 10.1016/S0966-842X(97)01054-8 · DOI · Paper page
  153. Park, 2014, Observation of inflammatory responses in mice orally fed with bacteriophage T7, J. Appl. Microbiol., 117, 627, 10.1111/jam.12565 · DOI
  154. Pirnay, 2011, The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?, Pharm. Res., 28, 934, 10.1007/s11095-010-0313-5 · DOI · Paper page
  155. Torres-Barceló, C. (2018). Phage Therapy Faces Evolutionary Challenges. Viruses, 10. · DOI
  156. Kolenda, C., Medina, M., Bonhomme, M., Laumay, F., Roussel-Gaillard, T., Martins-Simoes, P., Tristan, A., Pirot, F., Ferry, T., and Laurent, F. (2022). Phage Therapy against Staphylococcus aureus: Selection and Optimization of Production Protocols of Novel Broad-Spectrum Silviavirus Phages. Pharmaceutics, 14. · DOI
  157. Sanmukh, S.G., Santos, N.J., Barquilha, C.N., dos Santos, S.A., Duran, B.O., Delella, F.K., Moroz, A., Justulin, L.A., Carvalho, H.F., and Felisbino, S.L. (2021). Exposure to Bacteriophages T4 and M13 Increases Integrin Gene Expression and Impairs Migration of Human PC-3 Prostate Cancer Cells. Antibiotics, 10. · DOI
  158. Vellon, 2007, Up-regulation of αVβ3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner, Differentiation, 75, 819, 10.1111/j.1432-0436.2007.00241.x · DOI
  159. Bichet, 2021, Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy, iScience, 24, 102287, 10.1016/j.isci.2021.102287 · DOI · Paper page
  160. Hsiao, 2014, Size and cell type dependent uptake of silica nanoparticles, J. Nanomed. Nanotechnol., 5, 1
  161. Ackermann, 2004, Long-term bacteriophage preservation, WFCC Newsl., 38, 35
  162. Abdelrahman, F., Easwaran, M., Daramola, O.I., Ragab, S., Lynch, S., Oduselu, T.J., Khan, F.M., Ayobami, A., Adnan, F., and Torrents, E. (2021). Phage-Encoded Endolysins. Antibiotics, 10. · DOI · Paper page
  163. Szybalski, 2012, Chapter 7—Endolysins as Antimicrobials, Advances in Virus Research, Volume 83, 299, 10.1016/B978-0-12-394438-2.00007-4 · DOI · Paper page
  164. Brzozowska, 2011, The functions of bacteriophage proteins, Postep. Hig. I Med. Dosw., 65, 167, 10.5604/17322693.936090 · doi:10.5604/17322693.936090

Cited by

See all 36

Metadata

Authors
Atshan, S. S., Hamat, R. A., Aljaberi, M. A., Chen, J.-S., Huang, S.-W., Lin, C.-Y., Mullins, B. J., & Kicic, A.
Venue
Antibiotics
Publisher
MDPI AG
Published
2023-02-01
Volume
12
Issue
2
Pages
286
ISSN
2079-6382
Cited by
36
References
8
Language
en
Funders
E-Da Hospital (EDAHS111001)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections. https://app.cochat.ai/papers/10.3390/antibiotics12020286
The paper
Atshan, S. S., Hamat, R. A., Aljaberi, M. A., Chen, J.-S., Huang, S.-W., Lin, C.-Y., Mullins, B. J., & Kicic, A. (2023). Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections. Antibiotics. https://doi.org/10.3390/antibiotics12020286

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.